In vivo hormonal regulation of insulin-like growth factor binding protein-5 mRNA in the immature rat ovary.
OBJECTIVE
Despite the potential importance of insulin-like growth factor binding protein-5 (IGFBP-5) to follicular development, the hormonal regulation of this antigonadotropic IGFBP has not been investigated. Therefore, it was the objective of this study to eludicate the role of gonadotropins and estrogen in the in vivo regulation of IGFBP-5 mRNA expression.


METHODS
Two models of follicular development in immature rats were used. Specifically, rats were hypophysectomized and treated with FSH and/or diethylstilbestrol (DES). Alternatively, terminal follicular development was induced in intact immature rats by pregnant mare serum gonadotropin (PMSG) and hCG. The IGFBP-5 mRNA in whole ovarian RNA was assayed by Northern blot hybridization. Localization of expression in PMSG and hCG-stimulated ovaries was further assessed by in situ hybridization.


RESULTS
Expression of IGFBP-5 mRNA was increased in ovaries from hypophysectomized rats. Treatment with FSH and/or DES did not alter the abundance of this mRNA. Treatment with PMSG induced a transient increase in IGFBP-5 expression that was localized in a subset of alpha-inhibin-negative follicles. At later times after PMSG, IGFBP-5 expression persisted in the surface epithelium but was not detected in large preovulatory follicles. In vitro studies affirmed the antigonadotropic action of IGFBP-5.


CONCLUSIONS
In vivo expression of IGFBP-5 in the rat ovary is moderated by hormonal treatment both in terms of total expression and follicular localization.
Putowski
L T
LT
Department of Obstetrics and Gynecology, University of Maryland School of Medicine, Baltimore 21201-1559, USA.
Choi
D
D
Mordacq
J
J
Scherzer
W J
WJ
Mayo
K E
KE
Adashi
E Y
EY
Rohan
R M
RM
D000818:Animals; D002478:Cells, Cultured; D006063:Chorionic Gonadotropin / Q000494:pharmacology*; D004054:Diethylstilbestrol / Q000494:pharmacology; D005260:Female; D005640:Follicle Stimulating Hormone / Q000494:pharmacology*; D006064:Gonadotropins, Equine / Q000494:pharmacology*; D006107:Granulosa Cells / Q000166:cytology / Q000187:drug effects / Q000502:physiology; D006801:Humans; D007016:Hypophysectomy; D007265:Inhibins / Q000494:pharmacology; D018975:Insulin-Like Growth Factor Binding Protein 5 / Q000096:biosynthesis* / Q000494:pharmacology; D010053:Ovary / Q000378:metabolism*; D010455:Peptides / Q000494:pharmacology; D012333:RNA, Messenger / Q000096:biosynthesis; D051381:Rats; D017207:Rats, Sprague-Dawley; D011994:Recombinant Proteins / Q000494:pharmacology; D012741:Sexual Maturation; D014158:Transcription, Genetic / Q000187:drug effects*
D006063:Chorionic Gonadotropin; D006064:Gonadotropins, Equine; D018975:Insulin-Like Growth Factor Binding Protein 5; D010455:Peptides; D012333:RNA, Messenger; D011994:Recombinant Proteins; C094377:inhibin-alpha subunit; D007265:Inhibins; D004054:Diethylstilbestrol; D005640:Follicle Stimulating Hormone